Searched for
DERUXTECAN
AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...- AstraZeneca gets regulator's nod to market cancer drug in IndiaAstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now appro...
- GSK's antibiotic drug Augmentin is India's highest-selling brand with Rs 80 crore monthly saleEnhertu, a cancer drug by AstraZeneca, was the top-selling new drug in 2024 with sales of nearly Rs 58 crore. Over 3,100 new brands were la...
- Over 3k brands hit pharma mkt, cancer drug tops in salesIndia's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the top-seller, ref...
- Union Budget 2025: Key healthcare moves for cancer treatment & more at total industry allocation of Rs 98,311 croreIn the Union Budget 2025-26, Finance Minister Nirmala Sitharaman announces Rs 98,311 crore allocation for healthcare, introducing daycare c...
- Budget 2025 for healthcare: Big changes in import duty for lifesaving medicinesFinance Minister Nirmala Sitharaman presented the Union Budget 2025, highlighting measures to enhance healthcare affordability. Key initiat...
- NPPA asks companies to cut prices of three cancer drugs post tax reliefIn a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed drug manufacturer...
- GST Council spices things up: Here's what got cheaper overnight in IndiaGST Council Meeting decisions: The GST Council's meeting on Monday announced significant tax cuts to make essential goods and services more...
- Med in India: Quality, affordability, accessDrugs made locally, be it under patent or generic, must be of high and uniform quality. Variations in quality has dogged the domestic pharm...
- From tax tweaks to job incentive scheme, 25 key announcements by Nirmala Sitharaman in Union Budget 2024-25Budget 2024 Key Takeaways: Presenting the Budget, Finance minister Nirmala Sitharaman unveiled a host of significant booster for sectors su...
- Budget 2024: Cancer patients get relief but senior citizens missed the attentionThe Union Budget 2024, while significantly increasing health sector funding to ₹90,959 crore, failed to address the BJP’s poll promise of i...
- Budget 2024 at a glance: What's going down and what's moving upShea butter cosmetics — customs duty on shea nuts reduced to 15% from 30%. Stretchable clothes that contain spandex, such as jeans and tops...
- Budget 2024: Some relief for cancer patients and increased PLI allocation for pharmaUnion Budget 2024 benefits pharma, healthcare by exempting AstraZeneca's cancer drugs Trastuzumab Deruxtecan, Osimertinib, Durvalumab, boos...
- Budget 2024 Decoded: Your 2 minute guide to become a budget proBudget Decoded: Finance Minister Nirmala announced a host of steps for the economy, companies, markets and taxpayers in the Budget 2024. He...
- Union health ministry allocated Rs 90,958.63 cr in 2024-25 budgetThe Union health ministry receives a budget increase to Rs 90,958.63 crore for 2024-25. Customs duty exemptions on three cancer drugs annou...
- Budget 2024: Government proposes to fully exempt 3 cancer drugs from customs dutyThe government proposes to cut custom duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil. Finance Ministe...
- AstraZeneca bets on licencing deals, public-private partnerships for India growthBritish-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, re...
- 'Unheard-of' cancer drug trials slow tumor growth, extend life of patientsThe new study would change how medicine was practiced, cancer specialists said.
Load More
